DBV Technologies (NASDAQ:DBVT) Stock Price Expected to Rise, Citizens Jmp Analyst Says

DBV Technologies (NASDAQ:DBVT) had its price objective boosted by equities research analysts at Citizens Jmp from $45.00 to $47.00 in a report released on Friday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective indicates a potential upside of 135.00% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday, December 29th. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Sunday, February 8th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. HC Wainwright set a $40.00 target price on shares of DBV Technologies in a research report on Thursday, December 18th. Finally, Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a research note on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, DBV Technologies currently has an average rating of “Moderate Buy” and an average target price of $38.65.

DBV Technologies Stock Performance

DBV Technologies stock opened at $20.00 on Friday. DBV Technologies has a 52 week low of $5.30 and a 52 week high of $26.18. The stock has a market capitalization of $1.11 billion, a P/E ratio of -3.83 and a beta of -0.97. The stock has a fifty day moving average of $21.58 and a 200-day moving average of $17.28.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, March 26th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.96). The business had revenue of $0.64 million during the quarter, compared to analyst estimates of $1.06 million. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 310.56%. On average, research analysts forecast that DBV Technologies will post -7.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DBVT. Allworth Financial LP bought a new position in DBV Technologies in the 4th quarter valued at approximately $32,000. Royal Bank of Canada bought a new stake in DBV Technologies during the 4th quarter worth approximately $34,000. GAMMA Investing LLC grew its holdings in DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after acquiring an additional 744 shares during the last quarter. New York State Common Retirement Fund acquired a new position in DBV Technologies in the 3rd quarter valued at approximately $34,000. Finally, Truvestments Capital LLC increased its position in DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after acquiring an additional 1,620 shares during the period. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies News Summary

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.